Citigroup’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$28.8K Buy
31,294
+18,061
+136% +$21.9K ﹤0.01% 4716
2025
Q4
$16.9K Sell
13,233
-5,792
-30% -$7.78K ﹤0.01% 4914
2025
Q3
$24.7K Sell
19,025
-109,231
-85% -$143K ﹤0.01% 4752
2025
Q2
$154K Sell
128,256
-96,571
-43% -$107K ﹤0.01% 4185
2025
Q1
$243K Sell
224,827
-23,028
-9% -$32.3K ﹤0.01% 4087
2024
Q4
$434K Buy
247,855
+17,230
+7% +$32.1K ﹤0.01% 3933
2024
Q3
$445K Buy
230,625
+154,691
+204% +$303K ﹤0.01% 3797
2024
Q2
$134K Sell
75,934
-600,242
-89% -$1.47M ﹤0.01% 4076
2024
Q1
$1.83M Buy
676,176
+352,604
+109% +$851K ﹤0.01% 2505
2023
Q4
$715K Buy
323,572
+133,781
+70% +$286K ﹤0.01% 3115
2023
Q3
$550K Buy
+189,791
New +$496K ﹤0.01% 2988
2023
Q1
Sell
-61
Closed -$71 5697
2022
Q4
$71 Sell
61
-5
-8% -$6 ﹤0.01% 5654
2022
Q3
$0 Sell
66
-1,724
-96% -$2.61K ﹤0.01% 6101
2022
Q2
$3K Sell
1,790
-3,815
-68% -$9.44K ﹤0.01% 5783
2022
Q1
$20K Sell
5,605
-15,323
-73% -$52.9K ﹤0.01% 5143
2021
Q4
$82K Sell
20,928
-94,480
-82% -$442K ﹤0.01% 4827
2021
Q3
$761K Sell
115,408
-3,519
-3% -$23.2K ﹤0.01% 3296
2021
Q2
$733K Buy
118,927
+113,256
+1,997% +$605K ﹤0.01% 3450
2021
Q1
$26K Sell
5,671
-27,893
-83% -$153K ﹤0.01% 5097
2020
Q4
$201K Buy
33,564
+30,173
+890% +$198K ﹤0.01% 4981
2020
Q3
$25K Sell
3,391
-6,150
-64% -$42.5K ﹤0.01% 6028
2020
Q2
$38K Sell
9,541
-33,889
-78% -$118K ﹤0.01% 6192
2020
Q1
$110K Buy
43,430
+29,187
+205% +$95.9K ﹤0.01% 5266
2019
Q4
$50K Buy
14,243
+8,095
+132% +$28.5K ﹤0.01% 6306
2019
Q3
$28K Sell
6,148
-32,434
-84% -$255K ﹤0.01% 6524
2019
Q2
$475K Buy
38,582
+28,894
+298% +$368K ﹤0.01% 4477
2019
Q1
$128K Buy
9,688
+2,797
+41% +$29.5K ﹤0.01% 5517
2018
Q4
$60K Sell
6,891
-399
-5% -$3.11K ﹤0.01% 6088
2018
Q3
$55K Buy
7,290
+3,520
+93% +$25K ﹤0.01% 6448
2018
Q2
$22K Buy
3,770
+2,778
+280% +$15.8K ﹤0.01% 6868
2018
Q1
$6K Sell
992
-343
-26% -$2.25K ﹤0.01% 7168
2017
Q4
$8K Buy
1,335
+1,238
+1,276% +$6.78K ﹤0.01% 7110
2017
Q3
$0 Buy
97
+23
+31% +$97 ﹤0.01% 7344
2017
Q2
$0 Sell
74
-144
-66% -$683 ﹤0.01% 7416
2017
Q1
$1K Buy
+218
New +$1.38K ﹤0.01% 7086
2016
Q4
Sell
-2,557
Closed -$20K 7254
2016
Q3
$20K Sell
2,557
-545
-18% -$5K ﹤0.01% 6211
2016
Q2
$28K Sell
3,102
-20,648
-87% -$194K ﹤0.01% 5950
2016
Q1
$192K Buy
23,750
+14,883
+168% +$107K ﹤0.01% 5128
2015
Q4
$96K Buy
8,867
+8,791
+11,567% +$86.3K ﹤0.01% 5403
2015
Q3
$1K Sell
76
-41,427
-100% -$652K ﹤0.01% 7174
2015
Q2
$1M Buy
41,503
+39,964
+2,597% +$1.26M ﹤0.01% 3157
2015
Q1
$65K Sell
1,539
-3,277
-68% -$130K ﹤0.01% 5358
2014
Q4
$162K Buy
4,816
+3,782
+366% +$107K ﹤0.01% 4857
2014
Q3
$25K Buy
1,034
+720
+229% +$20.2K ﹤0.01% 5758
2014
Q2
$9K Sell
314
-3,736
-92% -$120K ﹤0.01% 6214
2014
Q1
$178K Sell
4,050
-4,918
-55% -$216K ﹤0.01% 4442
2013
Q4
$343K Buy
8,968
+8,657
+2,784% +$255K ﹤0.01% 4154
2013
Q3
$7K Buy
311
+78
+33% +$1.53K ﹤0.01% 6330
2013
Q2
$4K Buy
+233
New +$4.09K ﹤0.01% 6383

Other funds holding LAB

Citigroup's LAB Position: Q1 2026 in Review

Citigroup increased its Standard BioTools (LAB) stake by 136% in Q1 2026, buying an estimated $21.9K and bringing the position to 31,294 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4716.

Citigroup first reported a position in LAB in Q2 2013 and has held it in 49 quarters since. The position peaked at $1.83M in Q1 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Citigroup held 31,294 shares of Standard BioTools worth $28.8K as of Q1 2026.
  • Citigroup bought 18,061 Standard BioTools shares in Q1 2026, an estimated $21.9K.
  • Standard BioTools made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4716 holding.
  • Citigroup first reported a position in Standard BioTools in Q2 2013 and has held it in 49 quarters since.
  • Citigroup's Standard BioTools position peaked at $1.83M in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.